Join
today

Boliven PRO is more than just patent search

  • Build and save lists using the powerful Lists feature
  • Analyze and download your search results
  • Share patent search results with your clients

Patents »

US7291484: Processes for culturing E1-immortalized cells to increase product yields

Share

Filing Information

Inventor(s) Christopher A. Yallop ·
Assignee(s) Crucell Holland B.V. ·
Attorney/Agent(s) TraskBritt, P.C. ·
Primary Examiner Celine Qian ·
Assistant Examiner Laura M Mitchell ·
Application Number US11259245
Filing date 10/26/2005
Issue date 11/06/2007
Prior Publication Data
Predicted expiration date 05/06/2024
U.S. Classifications 435/691  · 435/383  · 435/375  · 435/455  · 435/703  ·
International Classifications C12N1500  · C12N502  · C12N506  · C12P2108  · C12P2300  ·
Kind CodeB2
Related U.S. Application DataCROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation of International Patent Application PCT/EP2004/050724, filed May 6, 2004, designating the United States of America, published, in English, as International Patent Publication WO 2004/099396 A1 on Nov. 18, 2004, which itself claims priority from International Patent Application Nos. PCT/EP03/50155 filed May 9, 2003, PCT/EP03/50390 filed Sep. 1, 2003, PCT/EP03/50940 filed Dec. 4, 2003, and PCT/EP04/050061 filed Jan. 30, 2004, the contents of the entirety of each of which are incorporated herein by this reference.
Foreign Priority WO20PCTEP0350155 - 05/09/2003 · WO20PCTEP0350390 - 09/01/2003 · WO20PCTEP0350940 - 12/04/2003 · WO20PCTEP0450061 - 01/30/2004 ·
24 Claims, 12 Drawings


Abstract

The invention provides processes for culturing cells derived from embryonic retinoblast cells immortalized by adenovirus E1 sequences, preferably PER.C6® (human embryonic retina) cells, to improve product yields from such cells. Feed strategies for such cells and cultures with very high cell densities are provided, resulting in high yields of products, such as recombinant antibodies.

Independent Claims | See all claims (24)

  1. 1. A method for culturing cells, said cells being human embryonic retina (HER) cells immortalized by adenovirus E1 sequences and able to grow in suspension, the method comprising the steps of: a) determining at least once during the culturing of the cells the concentration of at least one medium component selected from the group consisting of glucose, glutamine, phosphate, leucine, serine, isoleucine, arginine, methionine and cystine, and b) adding components to the medium during the culturing of the cells at or prior to the depletion of at least one of the components of which the concentration was determined in step a), wherein the components added at least comprise glucose, glutamine, phosphate, leucine, serine, isoleucine, arginine, methionine and cystine, wherein components in step b) are added to an end concentration in mmoles/l of freshly added component per 10×106 cells/ml of between 4.0 and 8.0 for glucose, 0.47 and 0.93 for phosphate, 0.44 and 0.88 for leucine, 0.37 and 1.47 for serine, 0.33 and 0.67 for isoleucine, 0.31 and 0.61 for arginine, 0.15 and 0.31 for methionine, and 0.1 and 0.6 for cystine.
  2. 18. A method for producing a product in HER cells immortalized by adenovirus E1 sequences, said cells being in a culture medium, wherein said product is chosen from the group consisting of a recombinant protein, a virus, and a recombinant adenovirus with a deletion in the E1 region, the method comprising the step of adding at least glutamine, glucose, phosphate, leucine, serine, isoleucine, arginine, methionine and cystine to the cluture medium to an end concentration in mmoles/liter of freshly added component per 10×106 cells/ml of between 1.01 and 3.46 for glutamine, 4.0 and 8.0 for glucose, 0.47 and 0.93 for phosphate, 0.44 and 0.88 for leucine, 0.37 and 1.47 for serine, 0.33 and 0.67 for isoleucine, 0.31 and 0.61 for arginine, 0.15 and 0.31 for methionine, and 0.1 and 0.6 for cystine.
  3. 20. A method for producing a product in HER cells immortalized by adenovirus E1 sequences, wherein said cells are cultured in a culture medium, comprising the step of the following components to the culture medium in the following amounts per liter: 3.6-21.6 mmoles glucose, 6.8-40.9 mmoles glutamine, 0.40-2.4 mmoles leucine, 2.31-13.9 mmoles serine, 0.3-1.8 mmoles isoleucine, 0.28-1.66 mmoles arginine, 0.14-0.83 mmoles methionine, 0.15-0.9 mmoles cystine, 0.27-1.62 mmoles valine, 0.26-1.58 mmoles lysine, .18-1.08 mmoles threonine, 0.06-0.36 mmoles asparagine, 0.078-0.47 mmoles tyrosine, 0.06-0.36 mmoles histidine, 0.012-0.072 mmoles phenylalanine, 0.036-0.22 mmoles tryptophan, and 0.45-2.7 mmoles phosphate.

References Cited

U.S. Patent Documents

Document NumberAssigneesInventorsIssue/Pub Date
US4703008 Kiren-Amgen, Inc. Lin Oct 1987
US4835260 Genetics Institute, Inc. Shoemaker May 1989
US5047335 The Regents of the University of Calif. Paulson et al. Sep 1991
US5192539 Akzo N.V. Van Der Marel et al. Mar 1993
US5441868 Kirin-Amgen, Inc. Lin Aug 1995
US5457089 Behringwerke Aktiengesellschaft Fibi et al. Oct 1995
US5494790 Kyowa Hakko Kogyo Co., Ltd. Sasaki et al. Feb 1996
US5631158 Creative BioMolecules, Inc. Dorai et al. May 1997
US5767078 Johnson et al. Jun 1998
US5773569 Affymax Technologies N.V. Wrighton et al. Jun 1998
US5789247 Ballay et al. Aug 1998
US5830851 Affymax Technologies N.V. Wrighton et al. Nov 1998
US5835382 The Scripps Research Institute Wilson et al. Nov 1998
US5856292 Colgate Palmolive Company Thomas et al. Jan 1999
US5856298 Amgen Inc. Strickland Jan 1999
US5994128 IntroGene B.V. Fallaux et al. Nov 1999
US6033908 b.v. IntroGene Bout et al. Mar 2000
US6395519 IntroGene B.V. Fallaux et al. May 2002
US6413746 Lonza Group, AG Field Jul 2002
US6475753 Human Genome Sciences, Inc. Ruben et al. Nov 2002
US6492169 Crucell Holland, B.V. Vogels et al. Dec 2002
US6506598 Genentech, Inc. Andersen et al. Jan 2003
US6558948 Kochanek et al. May 2003
US6653101 Alusuisse Holdings A.G. Cockett et al. Nov 2003
US6855544 Crucell Holland B.V. Hateboer et al. Feb 2005
US6878549 Introgene B.V. Vogels et al. Apr 2005
US20020116723 Grigliatti et al. Aug 2002
US20030087372* GENENTECH, INC. DelaCruz et al. May 2003
US20030087437 Asada et al. May 2003
US20030092160 Bout et al. May 2003

Foreign Patent Documents

Document NumberAssigneesInventorsIssue/Pub Date
EP0185573INSTITUT PASTEURJun 1986
EP0411678GENETICS INSTITUTE, INC.Feb 1991
EP0833934INTROGENE BVApr 1998
EP1108787Crucell Holland B.V.Jun 2001
WO199303163Feb 1993
WO199505465Feb 1995
WO199529994Nov 1995
WO199700326Jan 1997
WO199718318May 1997
WO199818926May 1998
WO199839411Sep 1998
WO199844141Oct 1998
WO199905268Feb 1999
WO199924068May 1999
WO200061164KENNETH S. WARREN LABORATORIESOct 2000
WO200063403INTROGENE B.V.Oct 2000
WO200105945INTROGENE B.V.Jan 2001
WO200138362CRUCELL HOLLAND B.V.May 2001
WO200218948CRUCELL HOLLAND B.V.Mar 2002
WO2002053580THE KENNETH S. WARREN INSTITUTE, INC.Jul 2002
WO2003003810THE INSTITUTE FOR SYSTEMS BIOLOGYMay 2003
WO2003048197CRUCELL HOLLAND B.V.Jun 2003
WO2003048348CRUCELL HOLLAND B.V.Jun 2003
WO2003051927CRUCELL HOLLAND B.V.Jun 2003
WO2004003176THE KENNETH S. WARREN INSTITUTE, INC.Jan 2004
WO2004099396CRUCELL HOLLAND B.V.Nov 2004
WO2004099396CRUCELL HOLLAND B.V.Nov 2004
* cited by examiner

Other Publications

Kurokawa, et al Biotech. Bioeng. 1994. vol. 44, pp. 95-103.*
Alkhatib et al., “Expression of Bicistronic Measles Virus P/C mRNA by Using Hybrid Adenovirus: Levels of C Protein Synthesized In Vivo Are Unaffected by the Presence or Absence of the Upstream P Initiator Codon,” Journal of Virology, Nov. 1988, pp. 4059-4068, vol. 62, No. 11.
Alkhatib et al., “High-Level Eurcaryotic In Vivo Expression of Biologically Active Measles Virus Hemagglutinin by Using an Adenovirus Type 5 Helper-Free Vector System,” Journal of Virology, Aug. 1988, pp. 2718-2727, vol. 62, No. 8.
Berg et al., High-Level Expression of Secreted Proteins from Cells Adapted to Serum-Free Suspension Culture, Research Report, BioTechniques 1993, pp. 972-978, vol. 14, No. 6.
Bout et al., “Improved helper cells for RCA-free production of El-deleted recombinant adenovirus vectors,” Cancer Gene Therapy, 1996, pp. S24, vol. 3, No. 6.
Bout et al., “Production of RCA-free batches of El-deleted recombinant adenoviral vectors on PER.C6,” Nucleic Acids Symp. Ser. 1998, XP-002115716, pp. 35-36.
Boutl et al., A novel packaging cell line (PER.C6) for efficient production of RCA-free batches of El-deleted recombinant adenoviral vectors, Cancer Gene Therapy, 1997, pp. S32-S33, vol. 4, No. 6.
Brown et al., “Evaluation of Cell Line 293 for Virus isolation in Routine Viral Diagnosis,” Journal of Clinical Microbiology, Apr. 1986, pp. 704-708, vol. 23, No. 4.
Bukreyev et al., “Recombinant Respiratory Syncytial Virus from Which the Entire SH Gene Has Been Deleted Grows Efficiently in Cell Culture and Exhibits Site-Specific Attenuation in the Respiratory Tract of the Mouse,” Journal of Virology, Dec. 1997, pp. 8973-8982, vol. 71, No. 12.
Caravokyri et al., “Constitutive Episomal Expression of Polypeptide IX (pIX) in a 293-Based Cell Line Complements that Deficiency of pIX Mutant Adenovirus Type 5,” Journal of Virology, Nov. 1995, pp. 6627-6633, vol. 69, No. 11.
Carroll et al., Abstract, Differential Infection of Receptor-modified Host Cells by Receptor-Specific Influenza Viruses, Virus Research, Sep. 1985, pp. 165-179, vol. 3, No. 2.
Certificate of deposit of the PER.C6 cell line (ECACC deposit under No. 96022940).
Ciccarone et al., “Lipofectamine 2000 Reagent for Transfection of Eukaryotic Cells,” Focus, 1999, pp. 54-55, vol. 21, No. 2.
Cote et al., Serum-Free Production of Recombinant Proteins and Adenoviral Vectors by 293SF-3F6 Cells, Biotechnology and Bioengineering, Sep. 5, 1998, pp. 567-575, vol. 59, No. 5.
Cronan, Abstract, Biotination of Proteins in-vivo a post-translational modification to label purify and study proteins, Journal of Biological Chemistry, Jun. 25, 1990, pp. 10327-10333, vol. 265, No. 18.
DuBridge et al., “Analysis of Mutation in Human Cells by Using an Epstein-Barr Virus Shuttle System,” Molecular and Cellular Biology, Jan. 1987, pp. 397-387, vol. 7, No. 1.
Endo et al., Growth of Influenza A Virus in Primary, Differentiated Epithetial Cells Derived from Adenoids, Journal of Virology, Mar. 1996, pp. 2055-2058, vol. 70, No. 3.
Fallaux et al, “New helper cells and matched early region I-deleted adenovirus vectors prevent generation of replication-competent adenoviruses,” Human Gene Therapy, Sep. 1, 1998, vol. 9, No. 1, pp. 1909-1917. Abstract.
Fallaux et al., Characterization of 911: A New Helper Cell Line for the Titration and Propagation of Early Region I-Deleted Adenoviral Vectors, Human Gene Therapy, Jan. 20, 1996, pp. 215-222, vol. 7.
Gallimore et al., Transformation of Human Embryo Retinoblasts with Simian Virus 40, Adenovirus and ras Oncogenes, Anticancer Research, 1986, pp. 499-508, vol. 6.
Garnier et al., Scale-up of the adenovirus expression system for the production of recombinant protein in human 293S cells, Cytotechnology, 1994, pp. 145-155, vol. 15.
GenBank Accession No. X02996.1, 1993, “Adenovirus type 5 left 32% of the genome.”
Ghosh-Choudhury et al., Protein IX, a minor component of the human adenovirus capsid, is essential for the packaging of the full length genomes, The EMBO Journal, 1987, pp. 1733-1739, vol. 6, No. 6.
GIBCO cell culture, A Guide to Serum-Free Cell Culture, www.invitrogen.com.
Grabenhorst et al., Construction of stable BHK-21 cells coexpressing human secretory glycoproteins and human Gal(beta-1-4)GlcNAc-R alpha-2,6-sialyltransferase alpha-2,6-Linked NeuAc is preferentially attached tot he Gal(beta-1-4)GlcNA(beta-1-2)Man(alpha-1-3)-branch of diantennary oligosaccharides from secreted recombinant beta-trace protein, Eur. J. Biochem, 1995, pp. 715-725, vol. 232, No. 3, Berlin, Germany.
Graham et al., “Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5,” J. Gen. Virol., 1997, pp. 59-72, vol. 36.
Graham et al., “Growth of 293 cells in suspension culture,” J Gen Virol, Mar. 1987, pp. 937-940, vol. 68.
Graham, Cell Lines, Promochem (visited Apr. 10, 2005) .
Grand et al., “Modulation of the level of expression of cellular genes in adenovirus 12-infected and transformed human cells,” Eur Mol Biol Organ J. 1986, 5 (6) 1253-1260. Abstract.
Grand et al., “The high levels of p53 present in adenovirus early region I-transformed human cells do not cause up-regulation of MDM2 expression,” Virology, 1995, vol. 210, No. 2, pp. 323-334. Abstract.
Hollister et al., Stable expression of mammalian betaI,4-galactosyltransferase extends the N-glycosylation pathway in insect cells, Glycobiology, 1998, pp. 473-480, vol. 8, No. 5, IRL Press, United Kingdom.
Holzer et al., “Construction of a Vaccinia Virus Deficient in the Essential DNA Repair Enzyme Uracil DNA Glycosylase by a Complementing Cell Line,” Journal of Virology, Jul. 1997, pp. 4997-5002, vol. 71, No. 7.
Inoue et al., Production of Recombinant Human Monoclonal Antibody Using ras-Amplified BHK-21 Cells in a Protein-free Medium, Biosci. Biotech. Biochem., 1996, pp. 811-817, vol. 60, No. 5.
Paul et al., Increased Viral Titer Through Concentration of Viral Harvests from Retroviral Packaging Lines, Human Gene Therapy, 1993, pp. 609-615, vol. 4.
Pazur et al., Abstract, Oligosaccharides as immunodeterminants of erythropoietin for two sets of anti-carbohydrate antibodies, Journal of Protein Chemistry, Nov. 2000, pp. 631-635, vol. 19, No. 8.
Pleschka et al., “A Plasmid-Based Reverse Genetics System for Influenza A Virus,” Journal of Virology, Jun. 1996, pp. 4188-4192, vol. 70, No. 6.
PubMed listing of abstracts (visited Apr. 10, 2005)
Reina et al., Comparison of Madin-Darby Canine Kidney cells ( MDCK) with a Green Monkey Continuous Cell Line (Vero) and Human Lung Embryonated Cells (MRC-5) in the Isolation of Influenza A Virus from Nasopharyngeal Aspirates by Shell Vial Culture, Journal of Clinical Microbiology, Jul. 1997, pp. 1900-1901, vol. 35, No. 7.
Rhim et al., “Development of Human Cell Lines from Multiple Organs,” Annals of the New York Academy of Sciences, 2000, pp. 16-25, vol. 919.
Schiedner et al., Abstract, Efficient transformation of primary human amniocytes by El functions of Ad5: generation of new cell lines for adenoviral vector production, 2000, Hum. Gene Ther. 11, 2105-2116.
Setoguchi et al., “Stimulation of Erythropoiesis by in vivo gene therapy: Physiologic consequences of transfer of the humanerythropoietin gene to experimental animals using an adenovirus vector,” Blood, Nov. 1, 1994, pp. 2946-2953, vol. 84, No. 9.
Spector et al., “Regulation of Integrated Adenovirus Sequences During Adenovirus Infection of Transformed Cells,” Journal of Virology, Dec. 1980, pp. 860-871, vol. 36, No. 3.
Stevens et al., “The N-Terminal Extension of the Influenza B Virus Nucleoproteins Is Not Required for Nuclear Accumulation or the Expression and Replication of a Model RNA,” Journal of Virology, Jun. 1998, pp. 5307-5312, vol. 72, No. 6.
Stockwell et al., High-throughput screening of small molecules in Miniaturized Mammalian Cell-based Assays involving Post-translational Modifications, Chemistry and Biology, Feb. 1999, pp. 71-83, vol. 6, No. 2.
Yallop et al., “PER.C6® Cells for the Manufacture of Biopharmaceutical Proteins,” Modern Biopharmaceuticals, ED. J. Knablein, 2005, WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany.
PCT International Search Report, PCT/EP2004/050724, dated Oct. 1, 2004.
PCT International Preliminary Report, PCT/EP2004/050724, dated Jan. 27, 2005.
Bout et al., “PER.C6 as production platform for human monoclonal antibodies,” Human Antibodies, Oct. 8, 2003, pp. 30, vol. 12, No. 1-2.
Jones et al., “High-Level Expression of Recombinant IgG in the Human Cell Line PER.C6,” Biotechnology Progress, Jan. 14, 2003, pp. 163-168, vol. 19.
Jones et al., “PER.C6 Cell LIne for Human Antibody Production: Crucell's Technology Maintains ‘Human’ Glycoylation Patterns,” Genetic Engineering News, May 15, 2002, pp. 50, 54, vol. 80, No. 5.
Xie et al., “Serum-Free Suspension Cultivation of PER.C6 Cells and Recombinant Adenovirus Production Under Different pH Conditions,” Biotechnology and Bioengineering, Dec. 5, 2002, pp. 569-579, vol. 80, No. 5.
Xie et al., “Large-Scale Propagation of a Replication-Defective Adenovirus Vector in Stirred-Tank Bioreactor PER.C6 Cell Culture Under Sparging Conditions,” Jul. 5, 2003, Biotechnology and Bioengineering, pp. 45-52, vol. 83, No. 1.
Pham et al., “Large-Scale Transient Transfection of Serum-Free Suspension-Growing HEK293 EBNA1 Cells: Peptone Additives Improve Cell Growth and Transfection Efficiency,” Biotechnology and Bioengineering, Nov. 5, 2003, pp. 332-342, vol. 84, No. 3.
U.S. Department of Health and Human Services, Public Health Service, Food and drug Administration, Center for Biologics Evaluation and Research, International Association for Biologicals, National Institute of Allergy and Infectious Diseases, National Vaccine Program Office, World Health Organization, Evolving Scientific and Regulatory Perspectives on Cell Substrates for Vaccine Development, Workshop, Friday, Sep. 10, 1999 (visited Sep. 30, 2005) .
Weikert et al., Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins, Nature Biotechnology, Nov. 1999, pp. 1116-1121, vol. 17, No. 11, Nature Pub. Co., New York, NY, US.
Yan et al., Novel Asn-linked oligosaccharides terminating in GaINAcAcbeta(1-4)[Fucalpha(1-3)]GlcNAcbeta(1-.) are present in recombinant human Protein C expressed in human kidney 293 cells, Glycobiology, 1993, pp. 597-608, vol. 3. No. 6.
Yeager et al., Constructing immortalized human cell lines, Current Opinion Biotechnology, 1999, pp. 465-469, vol. 10.
Yeh et al., Adenoviral Vectors, pp. 25-42 of “Concepts in Gene Therapy,” Publisher: Walter de Gruyter, New York, 1997.
Yu et al., “Enhanced c-erbB-2/neu expression in human overian cancer cells correlates with more severe malignancy that can be suppressed by E1A,” Cancer Res., 1993, 53 (4) 891-8. Abstract.
Zhang et al., Stable expression of human alpha-2,6-sialyltransferase in Chinese hamster ovary cells: functional consequences for human erythropoietin expression and bioactivity, BBA—General Subjects, 1998, pp. 441-452, vol. 1425, No. 3, Elsevier Science Publishers, NL.
NCBI Entrez Nucleotide accession No. U38242, 1995.
NCBI Entrez Nucleotide accession No. X02996 J01967 J01968 J01970 J01971 J01972 J01974 J01976 J01977 J01978 J01979 K00515 V00025 V00026 V00027 V00029, 1992.
Neumann et al., “Generation of influenza A viruses entirely from cloned cDNAs,” Proc. Natl. Acad. Sci., Aug. 1999, pp. 9345-9350, vol. 96.
Notice of Opposition of a European Patent for 1 161 548 by Serono, 2005.
Opposition against European patent 1 108 878 B1 filed Oct. 5, 2005 in the name and on behalf of CEVEC Phannaceuticals GmbH.
Opposition against European patent 1 161 548 B1 filed Nov. 16, 2005, in the name and on behalf of CEVEC Pharmaceutical GmbH.
Opposition against European patent 1108787 filed Oct. 5, 2005 in the name and on behalf of Probiogen AG.
Ory et al., “A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes,” Proc. Natl. Acad. Sci., Oct. 1996, pp. 11400-11406, vol. 93.
Pacitti et al., Inhibition of Reovirus Type 3 Binding to Host Cells by Sialylated Glycoproteins Is Mediated through the Viral Attachment Protein, Journal of Virology, May 1987, pp. 1407-1415, vol. 61, No. 5, American Society for Microbiology.
Parkinson et al., “Stable Expression of a Secretable Deletion Mutant of Recombinant Human Thrombomodulin in Mammalian Cells,” The Journal of Biological Chemistry, Jul. 25, 1990, pp. 12602-12610, vol. 265, No. 21.
Pau et al., Abstract, The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines, Vaccine, Mar. 21, 2001, pp. 2716-2721, vol. 19, No. 17-19.
Interlocutory Decision of the Opposition Division of Jul. 21, 2003 in the case EP 0 695 351(European application 94 913 174.2).
Jenkins et al., Getting the glycosylation right: Implications for the biotechnology industry, Nature Biotechnology, Aug. 1996, pp. 975-981, vol. 14, No. 8, Nature Publishing, US.
Lopez et al., Efficient production of biologically active human recombinant proteins in human lymphoblastoid cells form integrative and episomal expression vectors, Gene, 1994, pp. 285-291, vol. 148.
Louis et al., Cloning and Sequencing of the Cellular—Viral Junctions from the Human Adenovirus Type 5 Transformed 293 Cell Line, Virology, 1997, pp. 423-429, vol. 233.
Lutz et al., “The Product of the Adenovirus Intermediate Gene IX Is a Transcriptional Activator,” Journal of Virology, Jul. 1997, pp. 5102-5109, vol. 71, No. 7.
Manservigi et al., “Protection from Herpes Simplex Virus Type I Lethal and Latent Infections by Secreted Recombinant Glycoprotein B Constitutively Expression in Human Cells with a BK Virus Episomal Vector,” Journal of Virology, Jan. 1990, pp. 431-436, vol. 64, No. 1.
Marketing Authorization and Scientific Discussion for Xigris, 2002.
Massie et al., Improved Adenovirus Vector Provides Herpes Simplex Virus Ribonucleotide Reductase R1 and R2 Subunits Very Efficiently, Biotechnology, Jun. 1995, pp. 602-608, vol. 13.
Merten et al., Production of Influenza Virus in Cell Cultures for Vaccine Preparation, Exp Med Biol., 1996, pp. 141-151, vol. 397.
Minch et al., Tissue Plasminogen Activator Coexpressed in Chinese Hamster Ovary Cells with alpha(2,6)-Sialyltransferase Contains NeuAc-alpha(2,6)Gal-beta(1,4)Glc-N-AcR Linkages, Biotechnol. Prog., 1995, pp. 348-351, vol. 11, No. 3.
NCBI Entrez Nucleotide accession No. NC—002018.
* cited by examiner

Referenced By

Document NumberAssigneeInventorsIssue/Pub Date
US8008043 Crucell Holland B.V. Christopher A. Yallop Aug 2011
US8546123 --